Form 8-K - Current report:
SEC Accession No. 0001493152-25-006285
Filing Date
2025-02-13
Accepted
2025-02-13 10:45:10
Documents
24
Period of Report
2025-02-11
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 53179
2 ex4-1.htm EX-4.1 118837
3 ex4-2.htm EX-4.2 109372
4 ex5-1.htm EX-5.1 16232
5 ex10-1.htm EX-10.1 292597
6 ex99-1.htm EX-99.1 16128
7 ex99-2.htm EX-99.2 14839
8 ex5-1_001.jpg GRAPHIC 5504
9 ex5-1_003.jpg GRAPHIC 6407
10 ex5-1_002.jpg GRAPHIC 6863
11 ex99-1_001.jpg GRAPHIC 4336
  Complete submission text file 0001493152-25-006285.txt   1006051

Data Files

Seq Description Document Type Size
12 XBRL SCHEMA FILE lixt-20250211.xsd EX-101.SCH 3521
13 XBRL DEFINITION FILE lixt-20250211_def.xml EX-101.DEF 29974
14 XBRL LABEL FILE lixt-20250211_lab.xml EX-101.LAB 36554
15 XBRL PRESENTATION FILE lixt-20250211_pre.xml EX-101.PRE 26997
27 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5402
Mailing Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733
Business Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733 310 203 2902
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Filer) CIK: 0001335105 (see all company filings)

EIN.: 202903526 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39717 | Film No.: 25618040
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)